Despite major advances in prevention and treatment, FN remains one of the most frequent
and serious complications of cancer chemotherapy (ChT). It is a major cause of morbidity …

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines — University of
Southern Denmark Skip to main navigation Skip to search Skip to main content University of …

This paper describes the incidence, morbidity, mortality and aetiology of febrile neutropenia,
and presents clinical practice guidelines for chemoprophylaxis and primary prophylaxis with …

Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for
Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk …

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

Management of febrile neutropaenia: ESMO clinical practice guidelines — MD Anderson Cancer
Center Skip to main navigation Skip to search Skip to main content MD Anderson Cancer Center …

Despite major advances in prevention and treatment, FN remains one of the most frequent
and serious complications of cancer chemotherapy (ChT). It is a major cause of morbidity …

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines Management of
febrile neutropaenia: ESMO Clinical Practice Guidelines Ann Oncol. 2016 Sep;27(suppl 5):v111-v118 …

Despite major advances in prevention and treatment, FN remains one of the most frequent
and serious complications of cancer chemotherapy (ChT). It is a major cause of morbidity …

Despite major advances in prevention and treatment, FN remains one of the most frequent
and serious complications of cancer chemotherapy (ChT). It is a major cause of morbidity …